Pegilodecakin as Monotherapy or in Combination With Anti–PD-1 or TKI in Heavily Pretreated Patients With Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pegilodecakin as Monotherapy or in Combination With Anti-PD-1 or Tyrosine Kinase Inhibitor in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma (RCC): Final Results of Cohorts A, G, H, and I of IVY Phase I Study
Int. J. Cancer 2021 Mar 12;[EPub Ahead of Print], NM Tannir, KP Papadopoulos, DJ Wong, R Aljumaily, A Hung, M Afable, JS Kim, D Ferry, A Drakaki, J Bendell, A NaingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.